Last reviewed · How we verify
NCT05587361
Beta-Adrenergic Modulation of Drug Cue Reactivity
Phase 4 trial testing Propranolol in Tobacco Use Disorder in 80 participants. Currently enrolling.
1 March 2026
Quick facts
| Lead sponsor | University of Oklahoma |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | basic science |
| Enrollment | 80 |
| Start date | 26 November 2024 |
| Primary completion | 1 March 2026 |
| Estimated completion | 1 March 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Propranolol (propranolol) — full drug profile →
- Nicotine Patch (nicotine-patch) — full drug profile →
- Placebo Propranolol
- Placebo Patch
Conditions studied
- Tobacco Use Disorder — all drugs for Tobacco Use Disorder →
- Nicotine Dependence — all drugs for Nicotine Dependence →
- Cigarette Smoking — all drugs for Cigarette Smoking →
Sponsor
University of Oklahoma
Who can join
Adults 21 to 60, any sex, with Tobacco Use Disorder or Nicotine Dependence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05587361
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Propranolol
Trials testing the same drug.
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
- NCT05741164 — Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory · Phase 2 · not yet recruiting
- NCT07352228 — Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices · Phase 4 · enrolling by invitation
- NCT07354126 — Comparative Efficacy of Flunarizine and Propanolol in Pediatric Migraine · NA · recruiting
- NCT06960850 — Effects of Oral Propranolol on Induction-Delivery Interval During Induction of Labour With Oxytocin · NA · not yet recruiting
Other recruiting trials for Tobacco Use Disorder
Currently open trials in the same condition.
- NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients · NA · recruiting
- NCT06678672 — Contingency Management for Veteran Smokers Undergoing Major Elective Surgery · NA · recruiting
- NCT06006143 — Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2 · Phase 2 · active not recruiting
- NCT06883162 — Cannabis-Tobacco Co-Use Treatment Study · Phase 3 · recruiting
- NCT06798324 — tDCS Plus Varenicline for Smoking Cessation · Phase 4 · recruiting
Other University of Oklahoma trials
Trials by the same sponsor.
- NCT07219706 — Dietary Fiber and Time Restricted Eating · NA · recruiting
- NCT07494773 — Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection · Phase 1, PHASE2 · not yet recruiting
- NCT07014605 — Smoking Cessation Program for Lao People With HIV · NA · not yet recruiting
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07491653 — Fiber mHealth Intervention for Prediabetes · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05587361 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Oklahoma
- Last refreshed: 20 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05587361.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing